Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
431 Leser
Artikel bewerten:
(2)

Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020

NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as part of a Virtual Conference Series featuring leading companies from the life sciences industry. At the event, taking place on April 7, 2020, management teams will present a business overview and highlights using an online, digital meeting format.

The April 7 schedule follows, with presentations available at https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html:

10:00 a.m. EST, Ascentage Pharma (6855-HK)
10:30 a.m. EST, Maxcyte (MXCT-GB)
11:00 a.m. EST, CASI Pharmaceuticals (CASI)
11:30 a.m. EST, BioXcel Therapeutics (BTAI)
12:00 p.m. EST, Pharming Group NV (PHARM-NL)
12:30 p.m. EST, I-Mab Biopharma (IMAB)
1:00 p.m. EST, Incysus Therapeutics (private)
1:30 p.m. EST, Engage Therapeutics (private)
2:00 p.m. EST, NervGen Pharma (NGEN-CA)
2:30 p.m. EST, Camallergy (private)
3:00 p.m. EST, Yiviva (private)

Investors and others can register and access the conference at the Solebury Trout Virtual Global Healthcare Conference Series website: https://troutaccess.com/investor.php/c/Solebury_Trout_Virtual_Global_Healthcare_Conference.

Companies that have presented at prior days of the conference series on March 26, March 31, and April 2, 2020, have included:

Adrenomed (private), Affimed (NASDAQ:AFMD), AM-Pharma (private), ANTEV Limited (private), Apexigen (private), Aptorum Group (NASDAQ:APM), BerGenBio (BGBIO-NO), Catabasis Pharmaceuticals (NASDAQ:CATB), CerSci Therapeutics (private), ESSA Pharma (NASDAQ:EPIX), Evofem Biosciences (NASDAQ:EVFM), Faraday Pharma (private), Forbius (private), HaemaLogiX (private), Impact Therapeutics (private), Junshi Biosciences (1877-HK), Kineta (private), Landos Biopharma (private), Lineage Cell Therapeutics (NYSE American:LCTX), NeuroRx (private), Neximmune (private), NorthSea Therapeutics (private), OnKure Therapeutics (private), Paion (PA8-DE), Paradigm Biopharma (PAR-AU), PharmaMar (PHM-SE), Pieris Pharmaceuticals (NASDAQ:PIRS). Ryvu Therapeutics (RVU-PL), Sol-Gel Technologies (NASDAQ:SLGL), Targovax (TRVX-NO), Teon Therapeutics (private), and Vaccitech Limited (private).

More information on the event, including archived presentations when available and a list of presenters and companies potentially available for engagement with the investment community, can be found at www.troutaccess.com.

About Solebury Trout

Solebury Trout is a well-established Investor Relations and Corporate Communications firm. For more than 20 years, Solebury Trout has partnered with private and public companies across all sectors, offering fully outsourced investor relations, perception surveys, environmental, social and governance (ESG) evaluations, C-suite visibility programs, content development, media relations, digital and social media communications, crisis preparation and media and presentation training.

Solebury Trout is affiliated with Solebury Capital and is a subsidiary of The PNC Financial Services Group, Inc. Solebury Capital a premier equity capital markets advisory firm providing management teams and owners with independent advice and judgment honed in decades of experience in capital markets at leading investment firms across the globe. Since its founding in 2005, Solebury Capital has advised on over 700 successful transactions representing nearly $300B in proceeds.

Contact:

Thomas Hoffmann
646-378-2931
thoffman@soleburytrout.com

Disclaimer

"Solebury" is a marketing name for Solebury Trout LLC and Solebury Capital LLC. The services described herein may be performed by a combination of Solebury Trout LLC or Solebury Capital LLC. Solebury deal team members may be employees of either entity. Solebury is an affiliate of The PNC Financial Services Group, Inc., a diversified financial services company. Equity capital markets advisory and related services are provided by Solebury Capital LLC. Solebury Capital LLC, is a registered broker-dealer and member of FINRA and SIPC. This material does not constitute an offer to sell or a solicitation of an offer to buy any investment product or security.

SOURCE: Solebury Trout



View source version on accesswire.com:
https://www.accesswire.com/584081/Solebury-Trout-Announces-Additional-Virtual-Conference-Presentations-from-Life-Science-Companies-on-April-7-2020

© 2020 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.